Skyrizi (risankizumab-rzaa) is a prescription injection used for treating plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. Skyrizi is typically given once every 8 to 12 ...
AbbVie has completed a Phase 1 study titled “A Phase 1 Pharmacokinetic Study in Healthy Subjects to Evaluate the Bioavailability of Risankizumab Subcutaneous Administration With On-Body Injector ...
- SKYRIZI is now the only four-dose-a-year biologic for psoriasis with options to administer via a single-dose pen or prefilled syringe NORTH CHICAGO, Ill., Aug. 9, 2021 /PRNewswire/ -- AbbVie (NYSE: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results